LENSAR (NASDAQ:LNSR) vs. Adagio Medical (NASDAQ:ADGM) Head to Head Analysis

Adagio Medical (NASDAQ:ADGM) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Adagio Medical and LENSAR, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	0	0	0	0	0.00
LENSAR	0	2	0	0	2.00

LENSAR has a consensus target price of $15.00, suggesting a potential upside of 8.30%. Given LENSAR’s stronger consensus rating and higher probable upside, analysts plainly believe LENSAR is more favorable than Adagio Medical.

Valuation & Earnings

This table compares Adagio Medical and LENSAR”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	$266,000.00	42.83	-$2.13 million	N/A	N/A
LENSAR	$53.49 million	3.05	-$14.38 million	($2.72)	-5.09

Adagio Medical has higher earnings, but lower revenue than LENSAR.

Profitability

This table compares Adagio Medical and LENSAR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	160.59%	40.99%
LENSAR	-34.03%	-49.02%	-21.12%

Volatility and Risk

Adagio Medical has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Insider and Institutional Ownership

48.1% of Adagio Medical shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 53.5% of Adagio Medical shares are held by insiders. Comparatively, 38.5% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Adagio Medical beats LENSAR on 7 of the 11 factors compared between the two stocks.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.

About LENSAR

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.